Open-label, multiple-dose, drug interaction study to assess the effect of famotidine with or without tenofovir on the pharmacokinetics of atazanavir when given with ritonavir in HIV-infected subjects

Trial Profile

Open-label, multiple-dose, drug interaction study to assess the effect of famotidine with or without tenofovir on the pharmacokinetics of atazanavir when given with ritonavir in HIV-infected subjects

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Nov 2014

At a glance

  • Drugs Atazanavir (Primary) ; Famotidine; Ritonavir; Tenofovir disoproxil fumarate
  • Indications HIV infections
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Nov 2008 Actual patient number (40) added as reported by ClinicalTrials.gov.
    • 07 Apr 2008 Actual study completion date December 2007 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top